OBJECTIVE: Recent reports highlight the efficacy of small interfering RNA (siRNA) targeting SMAD3 to regulate transforming growth factor β (TGF-β)-mediated fibroplasia in vocal fold fibroblasts. The current study sought to investigate SMAD3 expression during wound healing in vivo and quantify the downstream transcriptional events associated with SMAD3 knockdown in vitro. STUDY DESIGN: In vivo and in vitro. METHODS: Unilateral vocal fold injury was created in a rabbit model. SMAD3 and SMAD7 mRNA expression was quantified at 1 hour and 1, 3, 7, 14, 30, 60, and 90 days following injury. In vitro, multi-gene analysis technology was employed in our immortalized human vocal-fold fibroblast cell line following TGF-β1 stimulation ± SMAD3 knockdown across time points. RESULTS: SMAD3 mRNA expression increased following injury; upregulation was significant at 3 and 7 days compared to control (both P < 0.001). SMAD7 mRNA was also upregulated at 3, 7, and 14 days (P = 0.02, P < 0.001, and P < 0.001, respectively). In vitro, SMAD3 knockdown reduced the expression of multiple profibrotic, TGF-β signaling, and extracellular matrix metabolism genes at 6 and 24 hours following TGF-β1 stimulation. CONCLUSION: Cumulatively, these data support SMAD3 as a potential master regulator of TGF-β-mediated fibrosis. SMAD3 transcription peaked 7 days following injury. Multi-gene analysis indicated that the therapeutic effectiveness of SMAD3 knockdown may be related to regulation of downstream mediators of fibroplasia and altered TGF-β signaling. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:E308-E316, 2017.
OBJECTIVE: Recent reports highlight the efficacy of small interfering RNA (siRNA) targeting SMAD3 to regulate transforming growth factor β (TGF-β)-mediated fibroplasia in vocal fold fibroblasts. The current study sought to investigate SMAD3 expression during wound healing in vivo and quantify the downstream transcriptional events associated with SMAD3 knockdown in vitro. STUDY DESIGN: In vivo and in vitro. METHODS: Unilateral vocal fold injury was created in a rabbit model. SMAD3 and SMAD7 mRNA expression was quantified at 1 hour and 1, 3, 7, 14, 30, 60, and 90 days following injury. In vitro, multi-gene analysis technology was employed in our immortalized human vocal-fold fibroblast cell line following TGF-β1 stimulation ± SMAD3 knockdown across time points. RESULTS:SMAD3 mRNA expression increased following injury; upregulation was significant at 3 and 7 days compared to control (both P < 0.001). SMAD7 mRNA was also upregulated at 3, 7, and 14 days (P = 0.02, P < 0.001, and P < 0.001, respectively). In vitro, SMAD3 knockdown reduced the expression of multiple profibrotic, TGF-β signaling, and extracellular matrix metabolism genes at 6 and 24 hours following TGF-β1 stimulation. CONCLUSION: Cumulatively, these data support SMAD3 as a potential master regulator of TGF-β-mediated fibrosis. SMAD3 transcription peaked 7 days following injury. Multi-gene analysis indicated that the therapeutic effectiveness of SMAD3 knockdown may be related to regulation of downstream mediators of fibroplasia and altered TGF-β signaling. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:E308-E316, 2017.
Authors: Yukie Yamaguchi; Takahisa Takihara; Roger A Chambers; Kristen L Veraldi; Adriana T Larregina; Carol A Feghali-Bostwick Journal: Sci Transl Med Date: 2012-05-30 Impact factor: 17.956
Authors: Judy W Lee; John P Tutela; Richard A Zoumalan; Vishal D Thanik; Phuong D Nguyen; Leon Varjabedian; Stephen M Warren; Pierre B Saadeh Journal: Arch Otolaryngol Head Neck Surg Date: 2010-07
Authors: Yanna Cao; Lu Chen; Weili Zhang; Yan Liu; Harry T Papaconstantinou; Craig R Bush; Courtney M Townsend; E Aubrey Thompson; Tien C Ko Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-08-10 Impact factor: 4.052
Authors: J R Jonsson; A D Clouston; Y Ando; L I Kelemen; M J Horn; M D Adamson; D M Purdie; E E Powell Journal: Gastroenterology Date: 2001-07 Impact factor: 22.682
Authors: Lucy Jean Dawes; Matthew Alexander Sleeman; Ian Keith Anderson; John R Reddan; Ian Michael Wormstone Journal: Invest Ophthalmol Vis Sci Date: 2009-06-10 Impact factor: 4.799
Authors: Ragini Vittal; Elizabeth A Mickler; Amanda J Fisher; Chen Zhang; Katia Rothhaar; Hongmei Gu; Krista M Brown; Amir Emtiazjoo; Jeremy M Lott; Sarah B Frye; Gerald N Smith; George E Sandusky; Oscar W Cummings; David S Wilkes Journal: PLoS One Date: 2013-10-21 Impact factor: 3.240
Authors: Nao Hiwatashi; Iv Kraja; Peter A Benedict; Gregory R Dion; Renjie Bing; Bernard Rousseau; Milan R Amin; Danielle M Nalband; Kent Kirshenbaum; Ryan C Branski Journal: Laryngoscope Date: 2017-12-14 Impact factor: 3.325
Authors: Eric K Tran; Yazeed Alhiyari; Kevin Juarez; Bhavani Shankara Gowda; Feng Schrader; Dipti P Sajed; Jennifer L Long Journal: Laryngoscope Investig Otolaryngol Date: 2022-09-26
Authors: Shigeyuki Mukudai; Iv Kraja; Renjie Bing; Danielle M Nalband; Mallika Tatikola; Nao Hiwatashi; Kent Kirshenbaum; Ryan C Branski Journal: Laryngoscope Investig Otolaryngol Date: 2019-10-22